Folotyn for Non-Hodgkin's Lymphoma Mahopac NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

THOMAS LESTER, MD
(914) 232-3135
111 Bedford Road
Katonah, NY
FAUZIA PARACHA, MD
(845) 562-6240
327 Fullerton Avenue
Newburgh, NY
Emil Hanna Wassef, MD
914-962-5151
352 Downing Dr
Yorktown Heights, NY
David Noah Shapiro, MD
203-791-6714
PO Box 368
Ridgefield, CT
Lincoln K Pa, MD
914-238-8464
140 S Bedford Rd
Chappaqua, NY
Javier A Ruiz, MD
(845) 561-4450
59 New Windsor Hwy Rte 32
New Windsor, NY
VANITA NORONHA, MD
(845) 561-7455
407 Gidney Avenue
Newburgh, NY
OYA TUGAL, MD
(914) 493-7997
19 Bradhurst Avenue
Hawthorne, NY
Craig Albert Usas, MD
914-945-0346
449 N State Rd
Briarcliff Manor, NY
Ping Zhou, MD
845-278-8373
71 Carriage Hill Rd
Brewster, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Mahopac NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Mahopac NY